Cancer societies and the Norwegian Ministry of Health and Care Services warmly invited to tune in live for the official launch of the long-awaited European Fair Pricing Network!

Due to the aging population and rising number of cancer cases across Europe, expenditure on cancer medicines is dramatically increasing. Lack of adequate access to both new and off-patent essential cancer medicines remains an issue - with high prices often cited as the main contributory factor. Moreover, overall prices of cancer medicines continue to rise, to the extent of impairing the capacity of health systems to provide affordable, population-wide access to cancer />
In response, European cancer societies and research institutes decided to come together and found the European Fair Pricing Network (EFPN) which, through research and advocacy, aims to secure fairer prices of cancer medicines while upkeeping the innovation pipeline and timely access for to promising new medicines for patients. Through research, EFPN seeks to collect and analyse reliable European data needed to measure challenges in the current pharmaceutical markets, and to develop new ways of organising innovation and sustainable supply of effective cancer medicines. EFPN will then translate research findings into tangible political asks directed at both national and European decision-makers.